Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1275, Issue 1, 2012, Pages 114-122

  Plomp, Jaap J ^a   Huijbers, Maartje G ^a   van der Maarel, Silvère M ^a   Verschuuren, Jan J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Electrophysiology; Mouse model; Muscle specific kinase; MuSK; Myasthenia gravis; Neuromuscular junction

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN G4; MUSCLE SPECIFIC KINASE; NEOSTIGMINE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; BYSTANDER EFFECT; DISEASE MODEL; EXPERIMENTAL MOUSE; HUMAN; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; SEROLOGY; VACCINATION;

EID: 84871555879     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06808.x     Document Type: Article

References (75)

1. Hoch, W., J. McConville, S. Helms, et al. 2001. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7: 365-368.
2. Lindstrom, J. 2004. Is "seronegative" MG explained by autoantibodies to MuSK Neurology 62: 1920-1921.
3. Shi, L., A.K. Fu & N.Y. Ip. 2012. Molecular mechanisms underlying maturation and maintenance of the vertebrate neuromuscular junction. Trends Neurosci. 35: 441-453.
4. Ghazanfari, N., K.J. Fernandez, Y. Murata, et al. 2011. Muscle specific kinase: organiser of synaptic membrane domains. Int. J. Biochem. Cell Biol. 43: 295-298.
5. Punga, A.R. & M.A. Ruegg. 2012. Signaling and aging at the neuromuscular synapse: lessons learnt from neuromuscular diseases. Curr. Opin. Pharmacol. 12: 340-346.
6. Wu, H., W.C. Xiong & L. Mei. 2010. To build a synapse: signaling pathways in neuromuscular junction assembly. Development 137: 1017-1033.
7. Burden, S.J. 2011. SnapShot: neuromuscular Junction. Cell 144: 826.
8. Dechiara, T.M., D.C. Bowen, D.M. Valenzuela, et al. 1996. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85: 501-512.
9. Kong, X.C., P. Barzaghi & M.A. Ruegg. 2004. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep. 5: 183-188.
10. Hesser, B.A., O. Henschel & V. Witzemann. 2006. Synapse disassembly and formation of new synapses in postnatal muscle upon conditional inactivation of MuSK. Mol. Cell Neurosci. 31: 470-480.
11. Kim, N., A.L. Stiegler, T.O. Cameron, et al. 2008. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135: 334-342.
12. Gomez, A.M. & S.J. Burden. 2011. The extracellular region of Lrp4 is sufficient to mediate neuromuscular synapse formation. Dev. Dyn. 240: 2626-2633.
13. Wu, H., Y. Lu, C. Shen, et al. 2012. Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation. Neuron 75: 94-107.
14. Yumoto, N., N. Kim & S.J. Burden. 2012. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 489: 438-442.
15. Farrugia, M.E. & A. Vincent. 2010. Autoimmune mediated neuromuscular junction defects. Curr. Opin. Neurol. 23: 489-495.
16. Verschuuren, J.J., J. Palace & N.E. Gilhus. 2010. Clinical aspects of myasthenia explained. Autoimmunity 43: 344-352.
17. Serra, A., R. Ruff, H. Kaminski & R.J. Leigh. 2011. Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles. Ann. N.Y. Acad. Sci. 1233: 26-33.
18. Leite, M.I., S. Jacob, S. Viegas, et al. 2008. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131: 1940-1952.
19. Zhang, B., J.S. Tzartos, M. Belimezi, et al. 2012. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 69: 445-451.
20. Pevzner, A., B. Schoser, K. Peters, et al. 2012. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J. Neurol. 259: 427-435.
21. Higuchi, O., J. Hamuro, M. Motomura & Y. Yamanashi. 2011. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 69: 418-422.
22. McConville, J., M.E. Farrugia, D. Beeson, et al. 2004. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55: 580-584.
23. Niks, E.H., Y. van Leeuwen, M.I. Leite, et al. 2008. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J. Neuroimmunol. 195: 151-156.
24. Ohta, K., K. Shigemoto, A. Fujinami, et al. 2007. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J. Neurol. 14: 1029-1034.
25. Tsiamalos, P., G. Kordas, A. Kokla, K. Poulas & S.J. Tzartos. 2009. Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur. J. Neurol. 16: 925-930.
26. Vincent, A. & J. Newsom-Davis. 1982. Acetylcholine receptor antibody characteristics in myasthenia gravis: I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin. Exp. Immunol. 49: 257-265.
27. Niks, E.H., J.B. Kuks, B.O. Roep, et al. 2006. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 66: 1772-1774.
28. Evoli, A., P.A. Tonali, L. Padua, et al. 2003. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126: 2304-2311.
29. Guptill, J.T., D.B. Sanders & A. Evoli. 2011. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 44: 36-40.
30. Guptill, J.T. & D.B. Sanders. 2010. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr. Opin. Neurol. 23: 530-535.
31. Selcen, D., T. Fukuda, X.M. Shen & A.G. Engel. 2004. Are MuSK antibodies the primary cause of myasthenic symptoms Neurology 62: 1945-1950.
32. Shiraishi, H., M. Motomura, T. Yoshimura, et al. 2005. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann. Neurol. 57: 289-293.
33. Hatanaka, Y., S. Hemmi, M.B. Morgan, et al. 2005. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 65: 1508-1509.
34. Punga, A.R., R. Flink, H. Askmark & E.V. Stalberg. 2006. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 34: 111-115.
35. Diaz-Manera, J., E. Martinez-Hernandez, L. Querol, et al. 2012. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78: 189-193.
36. Schroeder, H.W., Jr. & L. Cavacini. 2010. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125: S41-S52.
37. Aalberse, R.C., S.O. Stapel, J. Schuurman & T. Rispens. 2009. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 39: 469-477.
38. Daha, N.A., N.K. Banda, A. Roos, et al. 2011. Complement activation by (auto-) antibodies. Mol. Immunol. 48: 1656-1665.
39. Aalberse, R.C. & J. Schuurman. 2002. IgG4 breaking the rules. Immunology 105: 9-19.
40. van der Neut-Kolfschoten M., J. Schuurman, M. Losen, et al. 2007. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-1557.
41. Sitaru, C., S. Mihai & D. Zillikens. 2007. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch. Dermatol. Res. 299: 1-8.
42. Beck, L.H., Jr., R.G. Bonegio, G. Lambeau, et al. 2009. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361: 11-21.
43. Ferrari, S., G.C. Mudde, M. Rieger, et al. 2009. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 7: 1703-1710.
44. Rock, B., C.R. Martins, A.N. Theofilopoulos, et al. 1989. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N. Engl. J. Med. 320: 1463-1469.
45. Jha, S., K. Xu, T. Maruta, et al. 2006. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J. Neuroimmunol. 175: 107-117.
46. Shigemoto, K., S. Kubo, N. Maruyama, et al. 2006. Induction of myasthenia by immunization against muscle-specific kinase. J. Clin. Invest. 116: 1016-1024.
47. Xu, K., S. Jha, W. Hoch & S.E. Dryer. 2006. Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 143: 655-659.
48. Punga, A.R., M. Maj, S. Lin, et al. 2011. MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity. Eur. J. Neurosci. 33: 890-898.
49. Punga, A.R., S. Lin, F. Oliveri, et al. 2011. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp. Neurol. 230: 207-217.
50. Mori, S., S. Kubo, T. Akiyoshi, et al. 2012. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am. J. Pathol. 180: 798-810.
51. Viegas, S., L. Jacobson, P. Waters, et al. 2012. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp. Neurol. 234: 506-512.
52. Plomp, J.J., G.T. Van Kempen, M.B. De Baets, et al. 1995. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann. Neurol. 37: 627-636.
53. Richman, D.P., K. Nishi, S.W. Morell, et al. 2012. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch. Neurol. 69: 453-460.
54. Rose, N.R. & C. Bona. 1993. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol. Today 14: 426-430.
55. Burges, J., A. Vincent, P.C. Molenaar, et al. 1994. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 17: 1393-1400.
56. Vincent, A., M.I. Leite, M.E. Farrugia, et al. 2008. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann. N.Y. Acad. Sci. 1132: 84-92.
57. Cole, R.N., S.W. Reddel, O.L. Gervasio & W.D. Phillips. 2008. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann. Neurol. 63: 782-789.
58. Cole, R.N., N. Ghazanfari, S.T. Ngo, et al. 2010. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J. Physiol. 588: 3217-3229.
59. Kawakami, Y., M. Ito, M. Hirayama, et al. 2011. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 77: 1819-1826.
60. ter Beek, W.P., P. Martinez-Martinez, M. Losen, et al. 2009. The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. Am. J. Pathol. 175: 1536-1544.
61. Klooster, R., J.J. Plomp, M.G. Huijbers, et al. 2012. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135: 1081-1101.
62. Morsch, M., S.W. Reddel, N. Ghazanfari, et al. 2012. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors. Exp. Neurol. 237: 286-295.
63. Niks, E.H., J.B. Kuks, J.H. Wokke, et al. 2010. Pre- and postsynaptic neuromuscular junction abnormalities in MuSK myasthenia. Muscle Nerve 42: 283-288.
64. Bestue-Cardiel, M., d.C.-A. Saenz, J.L. Capablo-Liesa, et al. 2005. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 65: 144-146.
65. Mori, S., M. Kishi, S. Kubo, et al. 2012. 3, 4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis. J. Neuroimmunol. 245: 75-78.
66. Shultz, L.D., P.A. Schweitzer, S.W. Christianson, et al. 1995. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 154: 180-191.
67. Lux, A., S. Aschermann, M. Biburger & F. Nimmerjahn. 2010. The pro and anti-inflammatory activities of immunoglobulin G. Ann. Rheum. Dis. 69(Suppl 1): i92-i96.
68. Mori, S., S. Yamada, S. Kubo, J. Chen, et al. 2012. Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis. J. Neuroimmunol. 244: 1-7.
69. Valenzuela, D.M., T.N. Stitt, P.S. Distefano, et al. 1995. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 15: 573-584.
70. Plomp, J.J., G.T. Van Kempen & P.C. Molenaar. 1992. Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha-bungarotoxin-treated rats. J. Physiol. 458: 487-499.
71. Sons, M.S., N. Busche, N. Strenzke, et al. 2006. alpha-Neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction. Neuroscience 138: 433-446.
72. Apel, E.D., S.L. Roberds, K.P. Campbell & J.P. Merlie. 1995. Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. Neuron 15: 115-126.
73. Pilgram, G.S., S. Potikanond, R.A. Baines, et al. 2010. The roles of the dystrophin-associated glycoprotein complex at the synapse. Mol. Neurobiol. 41: 1-21.
74. Strochlic, L., A. Cartaud & J. Cartaud. 2005. The synaptic muscle-specific kinase (MuSK) complex: new partners, new functions. Bioessays 27: 1129-1135.
75. Noakes, P.G., M. Gautam, J. Mudd, et al. 1995. Aberrant differentiation of neuromuscular junctions in mice lacking s-laminin/laminin beta 2. Nature 374: 258-262.